Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

David L. MacLeod1*, Lynn M. Barker1, Jennifer L. Sutherland1, Suzanne C. Moss1, Jesse L. Gurgel1, Thomas F. Kenney1, Jane L. Burns2 and William R. Baker1

1Gilead Sciences, Inc., Seattle, WA 98121, USA; 2University of Washington School of Medicine, Division of Infectious Diseases, Department of Pediatrics, Seattle, WA 98195, USA

Received 29 May 2009; returned 24 June 2009; revised 10 July 2009; accepted 10 July 2009

Objectives: To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) with those of fosfomycin and tobramycin alone against cystic fibrosis (CF) and non-CF bronchiectasis pathogens.

Methods: Clinical isolates of CF Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, Stenotrophomonas maltophilia, Burkholderia cepacia complex, Escherichia coli and Klebsiella spp. were evaluated by MIC, MBC, post-antibiotic effect (PAE), synergy, time–kill, a rat pneumonia model and spontaneous mutation frequency (SMF).

Results: FTI showed high activity against E. coli, H. influenzae, S. aureus and Klebsiella spp. For the S. aureus strains, 75% of which were methicillin resistant (MRSA), FTI had a lower MIC90 than tobramycin. For P. aeruginosa, FTI had a lower MIC90 than fosfomycin, but tobramycin was more active than either. Synergy studies showed no antagonism between fosfomycin and tobramycin, and 93% of the isolates demonstrated no interaction. FTI was rapidly bactericidal and exhibited concentration-dependent killing in time–kill studies. In the rat pneumonia model, FTI and tobramycin demonstrated bactericidal killing of P. aeruginosa; both were more active than fosfomycin alone. The SMF for S. aureus resistance to FTI was 2–4 log10 lower than that for tobramycin and 2–7 log10 lower than that for fosfomycin. For P. aeruginosa, the FTI SMF was 2–3 log10 lower than that for fosfomycin and 1–2 log10 lower than that for tobramycin.

Conclusions: FTI is a broad-spectrum antibiotic combination with high activity in vitro and in vivo. These data suggest FTI could be a potential treatment for respiratory infections caused by Gram-positive and Gram-negative aerobic bacteria.

Keywords: P. aeruginosa, S. aureus, respiratory infections

Introduction

Cystic fibrosis (CF) and non-CF bronchiectasis patients are predisposed to chronic respiratory infections caused by a variety of bacteria including Pseudomonas aeruginosa, Staphylococcus aureus and non-typeable Haemophilus influenzae. Stenotrophomonas maltophilia, Achromobacter xylosoxidans and Burkholderia cepacia complex are also frequent pathogens in CF1,2 and Moraxella catarrhalis, Streptococcus pneumoniae and enteric Gram-negative bacilli are seen in non-CF bronchiectasis.3 Extensive use of intravenous, oral and inhaled antibiotics has improved the survival of CF patients4,5 but has also led to the development of bacterial resistance.6,7 There is a clear need for new antibiotics, and novel approaches including combination drugs should be explored.

An ideal therapy would be delivered directly to the lungs, kill a broad spectrum of bacteria, have a favourable safety profile and reduce the development of resistance. A combination antibiotic consisting of fosfomycin and tobramycin may be an appropriate addition to the current treatments for the management of respiratory infections. Fosfomycin is a phosphonic acid antibiotic8 with

*Corresponding author. Tel: +1-206-728-5090, ext. 3024; Fax: +1-206-728-5095; E-mail: Dave.MacLeod@gilead.com

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use distribution, and reproduction in any medium, provided the original work is properly cited.
little reported human toxicity when administered parenterally. It is active against both Gram-positive and Gram-negative bacteria, and inhibits the first step of peptidoglycan biosynthesis in the bacterial cell wall. Both oral (fosfomycin calcium and fosfomycin trometamol) and intravenous (fosfomycin disodium) formulations are available, but only oral fosfomycin trometamol is approved in the USA for treating uncomplicated urinary tract infections. Parenteral administration of fosfomycin is sporadically used in the UK to treat CF bacterial respiratory infections, but oral formulation deliverable directly to the lungs has not yet been developed.

Tobramycin is an aminoglycoside and is highly potent against Gram-negative bacteria, in particular P. aeruginosa. Tobramycin is rapidly bactericidal and acts by inhibiting bacterial protein synthesis. Aerosolized tobramycin (TOBI) is used for the management of P. aeruginosa respiratory infections in CF patients. Nephrotoxicity and otoxicity are adverse reactions associated with tobramycin therapy. The greatest risk factor for development of toxicity is cumulative exposure to large doses of tobramycin. Bronchiectasis patients may be at increased risk of developing tobramycin toxicity because they receive prolonged and repeated antibiotic therapies over their lifetime.

The purpose of this study was to evaluate the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) against bacterial respiratory pathogens seen in the CF and non-CF bronchiectasis populations, and to compare them with those of fosfomycin and tobramycin, individually. S. aureus and P. aeruginosa were the major focus of this work, both because of their frequency and virulence in bronchiectasis infections and because, as resistance increases in these two organisms, treatment becomes problematic.

Materials and methods

Bacterial strains

P. aeruginosa strains from patients with CF (n = 100) were obtained from the Therapeutics Development Network Center for CF Microbiology at the Children’s Hospital and Regional Medical Center (Seattle, WA, USA). B. cepacia (n = 20) complex strains were obtained from the University of British Columbia (Vancouver, BC, Canada). Non-CF (respiratory, bloodstream, skin/soft tissue) P. aeruginosa (n = 60), Enterococcus faecalis (n = 5), E. coli (n = 22), H. influenzae (n = 16), Klebsiella spp. (n = 22), M. catarrhalis (n = 5), S. maltophilia (n = 17), S. aureus (n = 16), S. pneumoniae (n = 8) and Streptococcus pyogenes (n = 5) strains were obtained from The Jones Group Laboratories (North Liberty, IA, USA) and The Clinical Microbiology Institute (Wilsonville, OR, USA). P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. aureus ATCC 29213, S. pneumoniae ATCC 49619, E. faecalis ATCC 29212 and H. influenzae ATCC 49247 served as quality control and reference strains. An animal-passaged derivative of P. aeruginosa ATCC 27853 (C177) was used in the rat pneumonia studies.

Antibiotics

Fosfomycin disodium, tobramycin sulphate and vancomycin hydrochloride were obtained from Sigma-Aldrich (St Louis, MO, USA). Ciprofloxacin hydrochloride was obtained from Cellgro (Herndon, VA, USA). FTI consisted of a 4:1 ratio (w/w basis) of fosfomycin and tobramycin. Glucose-6-phosphate (Sigma-Aldrich) was added to the media at a final concentration of 25 mg/L for all in vitro evaluations of fosfomycin and FTI.

MICs and MBCs

MICs were determined by agar plate dilution and broth microdilution methods. The MIC was defined as the lowest concentration of antibiotic that prevented visible growth after incubation at 35°C for 18–24 h. FTI MIC values were expressed as the concentration of both drugs (example, FTI MIC of 8 mg/L = 6.4 mg/L fosfomycin + 1.6 mg/L tobramycin). Vancomycin and ciprofloxacin MICs were determined only for the S. aureus isolates. MBCs were determined according to CLSI (formerly NCCLS) guidelines. The MBC was defined by a ≥3 log10 decrease in cfu/mL of the original inoculum.

Chequerboard synergy

Interactions between fosfomycin and tobramycin were determined by the broth microdilution chequerboard method. Two-fold serial dilutions bracketing the expected MIC value of both antibiotics were evaluated. The fractional inhibitory concentration (FIC) was calculated as the MIC of compound 1 in combination with a second compound, divided by the MIC of compound 1 alone. An FIC index (FICI) was calculated for each drug combination as the sum of the individual FICs of compounds 1 and 2. Synergy was defined as an FICI of ≤0.5, no interaction as an FICI >0.5 and ≤4, and antagonism as an FICI >4. The lowest FICI was used for final interpretation of drug interactions.

Post-antibiotic effect (PAE)

PAE values were determined by the viable plate count method. Bacteria were incubated with antibiotic at ≥4× the MIC for 1–2 h in a shaking 35°C water bath. Growth controls were included in each experiment. Following exposure, the cultures were diluted 1:1000 and the cfu/mL determined hourly. The PAE was defined as T–C, where T is the time required for the viable counts of an antibiotic-exposed culture to increase 1 log10 cfu/mL above the counts determined immediately after dilution and C is the corresponding time for the growth control.

Time–kill studies

Time–kill experiments were performed according to CLSI standards. Antibiotics were evaluated at multiples of the MIC in cation-adjusted Mueller–Hinton broth (CAMHB) (Remel, Lenexa, KS, USA). A no-drug control was run in each assay. Bacterial cultures and antibiotic were incubated at 35°C in a shaking water bath and killing activity assessed at 1, 2, 4, 6 and 24 h. Antibiotic concentrations that reduced the original inoculum by ≥3 log10 cfu/mL were considered bactericidal.

Animal efficacy studies

Animals were handled according to the Guidelines for the Care and Use of Laboratory Animals. All animal protocols were approved by an IRB/Ethics Committee. Male Sprague–Dawley rats (180–200 g) were obtained from Charles River Laboratories (Hollister, CA, USA) and acclimatized for 5 days prior to use. Animals were housed individually in ventilated cages, fed Purina Lab Diet ad libitum and allowed free access to water.
Antibiotic efficacy was determined using a rat bacterial pneumonia model. Rats were anaesthetized with isoflurane, and ~10^7 cfu of P. aeruginosa C177 in a 2% agar solution were instilled into the lungs with an oral gavage needle. The inoculum was deposited at the first bifurcation and distributed throughout the lungs by inspiration. Animals were allowed to recover for 18 h post-infection. Each experiment consisted of pre-treatment (n=5–7), saline control (n=5–7) and antibiotic (n=5–7) groups. Rats were anaesthetized with isoflurane, and 100 µL of antibiotic solution or saline was instilled into the trachea using a Microsprayer™ (Penn-Century Inc., Philadelphia, PA, USA). Antibiotics were administered intratracheally twice daily for 3 days.

Animals were euthanized by intraperitoneal administration of sodium pentobarbital. The pre-treatment control group was harvested 18 h post-infection, and the saline and treatment groups 18 h after the last antibiotic exposure. Lungs were removed aseptically, homogenized in sterile normal saline and viable bacteria determined by the colony count method. Statistical differences between the saline control group and treatment groups were evaluated by the Mann–Whitney Rank Sum Test using GraphPad Prism® software package version 3.03 (GraphPad Software, Inc., San Diego, CA, USA).

Single-step resistance

Development of resistance after a single exposure to antibiotic was determined using four clinical and one reference strain of S. aureus and P. aeruginosa. Late log-phase cultures (10^9–10^10 cfu) were spread onto Mueller–Hinton agar (BBL, Sparks, MD, USA) plates containing 4x the MIC of each antibiotic. The culture plates were incubated at 35°C for 48 h and the number of colonies on each plate was enumerated manually. The frequency of resistance was calculated by dividing the number of bacteria growing at the defined antibiotic concentration by the number of bacteria in the inoculum. MIC values were calculated for three representative spontaneous mutants and compared with those for the parental strain.

Results

MICs

Table 1 summarizes the MICs at which 50% (MIC_{50}) and 90% (MIC_{90}) of the clinical isolates were inhibited. FTI had high activity against the 16 random S. aureus strains, and moderate activity against S. pneumoniae, S. pyogenes and E. faecalis. Twelve of the 16 S. aureus strains were categorized as methicillin-resistant (MRSA). The FTI MIC_{50} value (2 mg/L) was nearly identical to that of vancomycin (1 mg/L) and was superior to that of ciprofloxacin (>4 mg/L) for S. aureus. FTI was also active against single linezolid-resistant (C059) and glycopeptide-intermediate S. aureus (GISA) (C060) isolates, with MICs of 2 and 1 mg/L, respectively.

Among the Gram-negative organisms examined FTI had the lowest MIC_{50} for E. coli (0.5 mg/L), H. influenzae (0.5 mg/L), Klebsiella spp. (1 mg/L) and P. aeruginosa (non-CF, 4 mg/L; and CF, 8 mg/L) strains. FTI also had high activity against M. catarrhalis strains, but poor activity against S. maltophilia and B. cepacia complex. Against tobramycin-resistant and high fosfomycin MIC (>128 mg/L) strains, FTI had MICs comparable to that of the most active single antibiotic component. Tobramycin had the lowest MIC_{50} and MIC_{90} values for the CF (2 and 16 mg/L) and non-CF P. aeruginosa (1 and 128 mg/L) strains. Fosfomycin had potent activity against S. aureus, H. influenzae, E. coli and Klebsiella spp. It showed moderate activity against P. aeruginosa and S. maltophilia, and poor activity against B. cepacia complex.

MBCs

FTI and tobramycin were bactericidal against the S. aureus (100%), S. pneumoniae (100%), P. aeruginosa (100%), E. coli (100%), Klebsiella spp. (100%) and H. influenzae (83% and

Table 1. MICs of FTI, tobramycin and fosfomycin for Gram-positive and Gram-negative bacteria

| Organism (no. of strains) | MIC (mg/L) | FTI | tobramycin | fosfomycin |
|---------------------------|------------|-----|------------|------------|
|                           | range      | MIC_{50} (MIC_{90}) | range | MIC_{50} (MIC_{90}) | range | MIC_{50} (MIC_{90}) |
| S. aureus** (16)          | 0.5–16     | 2 (8) | 0.125–512  | 0.5 (256) | 0.125–16 | 2 (4) |
| S. pneumoniae** (8)       | 4–32       | ND  | 16–64      | ND         | 8–32     | ND |
| S. pyogenes** (5)         | 16–32      | ND  | 16–64      | ND         | 16–64    | ND |
| E. faecalis** (5)         | 32         | ND  | 8–512      | ND         | 32       | ND |
| E. coli** (22)            | 0.125–1    | 0.5 (1) | 0.5–1      | 1 (1)     | 0.25–4   | 0.5 (2) |
| H. influenzae** (16)      | <0.13–4    | 0.5 (2) | 0.5–1      | 1 (1)     | 0.25–4   | 0.5 (2) |
| Klebsiella spp.** (22)    | 0.5–16     | 1 (8) | 0.13–512   | 0.13 (16) | 0.5–16   | 4 (16) |
| M. catarrhalis** (5)      | 0.5–1      | ND   | 0.13–512   | 0.13 (16) | 0.5–16   | 4 (16) |
| P. aeruginosa*, non-CF (60)| 1–256     | 4 (128) | 0.13–512   | 1 (128)   | 1–512    | 32 (128) |
| P. aeruginosa*, CF (100)  | 1–128      | 8 (64) | 0.25–512   | 2 (16)    | 4–512    | 64 (512) |
| S. maltophilia* (17)      | 8–256      | 64 (128) | 2–512      | 64 (256)  | 32–512   | 64 (128) |
| B. cepacia complex* (20)  | 0.5–512    | 512 (>512) | 1–512      | 64 (512)  | 512–>512 | >512 (>512) |

ND, not determined due to the small number of isolates examined.

** MICs were determined by the agar dilution method.

* MICs were determined by the broth microdilution method.
Table 2. MBC/MIC ranges of clinical strains

| Organism (no. of strains) | Range of MBC/MICa | FTI | Tobramycin | Fosfomycin |
|---------------------------|-------------------|-----|------------|------------|
| S. aureus (10)            | 1–2               | 1–2 | 1–8        |
| S. pneumoniae (7)         | 1–4               | 1–2 | 1–16       |
| P. aeruginosa, non-CF (10)| 1–4               | 1–2 | 2–8        |
| P. aeruginosa, CF (8)     | 1–4               | 1–4 | 2–>16      |
| E. coli (10)              | 1–4               | 1–4 | 1–8        |
| Klebsiella spp. (5)       | 1                 | 1–4 | 1–4        |
| H. influenzae (6)         | 1–8               | 1–2 | 1–8        |

The MBC/MIC ratio was calculated by dividing the MBC (mg/L) by the MIC (mg/L).

Table 3. PAE of FTI, tobramycin and fosfomycin for S. aureus, P. aeruginosa and E. coli

| Organism | Antibiotic | MIC (mg/L) | PAE (h) |
|----------|------------|------------|---------|
| S. aureus ATCC 29213 | FTI        | 2.0        | 3.8     |
|           | tobramycin | 0.5        | 2.8     |
|           | fosfomycin | 2.0        | 1.3     |
| P. aeruginosa ATCC 27853 | FTI        | 4.0        | 3.0     |
|           | tobramycin | 0.5        | 2.0     |
|           | fosfomycin | 4.0        | 1.0     |
| E. coli ATCC 25922      | FTI        | 1.0        | 2.8     |
|           | tobramycin | 0.5        | 2.5     |
|           | fosfomycin | 2.0        | 1.0     |

PAE was determined after a 2 h exposure to 2× the MIC of antibiotic.

Animal efficacy studies
In the absence of antibiotic treatment, cfu/lung decreased <1 log_{10} at days 4 and 7 post-infection. Intratracheal administration of FTI showed progressively greater killing of P. aeruginosa with increasing dose (Figure 2). In subsequent experiments, complete eradication of the C177 infection was seen with 5 and 12.5 mg/kg FTI. Tobramycin showed 3 log_{10} bacterial killing at 2.5 mg/kg. Administration of tobramycin doses higher than 3 mg/kg resulted in complete eradication of the P. aeruginosa infection, while doses ≤0.5 mg/kg did not result in bacterial killing. A reduction in cfu/lung was not observed after administration of ≤10 mg/kg fosfomycin.

Discussion
This study investigated the in vitro and in vivo antibacterial activities of FTI, a novel inhaled antibiotic combination. Fosfomycin was selected as the major component because it is active against both Gram-positive and Gram-negative bacteria,12 is bactericidal10 and has a good safety profile.5 However, fosfomycin kills in a time-dependent fashion,10 is only moderately active against P. aeruginosa and some of the more resistant Gram-negative organisms,12 and has a high mutation frequency resulting in bacterial resistance in vivo.26,27 Tobramycin is rapidly bactericidal, exhibits concentration-dependent killing activity,16 is highly active against many resistant Gram-negatives15 and has a low prevalence of bacterial resistance. Tobramycin constitutes the minor component because of the benefits of reducing the lifetime accumulation of aminoglycoside toxicity,18 which can be minimized by lowering the dose of tobramycin.

Polymicrobial respiratory infections are a significant cause of morbidity and mortality in CF and non-CF bronchiectasis patients23 as well as other diseases characterized by chronic...
airway infection. Important pathogens common to both populations include *S. aureus*, *P. aeruginosa* and non-typeable *H. influenzae*. FTI demonstrated excellent activity against both *S. aureus* and *H. influenzae*. *S. aureus* may be particularly pathogenic and the prevalence of MRSA is increasing. We demonstrated that FTI had high activity against ciprofloxacin- and methicillin-resistant *S. aureus*, suggesting that it might be a good therapeutic agent for these infections. Neither CF nor non-CF *P. aeruginosa* was found to be as susceptible to FTI as it was to tobramycin when susceptibility testing was conducted by CLSI standards. However, *in vitro* antibiotic activity does not always correlate with *in vivo* activity, particularly in CF because CF sputum has been shown to inhibit the activity of aminoglycosides. FTI demonstrated relatively poor activity against other CF pathogens, particularly *S. maltophilia* and *B. cepacia* complex. However, it was active against other non-CF bronchiectasis pathogens including *M. catarrhalis*, *E. coli*, *Klebsiella* and *S. pneumoniae*.

Examination of synergy by the chequerboard method demonstrated no interaction between fosfomycin and tobramycin for the majority of clinical *P. aeruginosa*, *E. coli* and *S. aureus* strains. Antagonism was not observed, while synergy was detected in 7% of the strains. To our knowledge this is the first report describing the interactions between fosfomycin and
Our results were consistent with those reported between fosfomycin and other aminoglycosides. The PAE of FTI was superior to that of fosfomycin and tobramycin for all three bacterial species. These data were consistent with time–kill kinetics, which also demonstrated slower bacterial regrowth with FTI compared with tobramycin or fosfomycin.

Time–kill experiments were conducted to evaluate the rate and degree of bacterial killing. FTI and tobramycin were rapidly bactericidal against *P. aeruginosa* and *S. aureus*. FTI killed in a concentration-dependent fashion, which is somewhat surprising because fosfomycin, the major component of the combination, killed in a time-dependent fashion. Tobramycin killed in a concentration-dependent fashion like other aminoglycoside antibiotics. We also demonstrated that fosfomycin was bactericidal against *S. aureus*, which is consistent with previous studies. Tobramycin’s mechanism of killing against *P. aeruginosa* is not well characterized. This study demonstrates that bactericidal killing is not reached at concentrations ≤16× the fosfomycin MIC for *P. aeruginosa* ATCC 27853. MBC experiments also confirmed that FTI reached bactericidal killing against clinical *P. aeruginosa*, *S. aureus* and *E. coli* strains.

The *in vitro* studies with FTI were supported by animal efficacy experiments in rats. Lung cfus were stable over the treatment period (3 days) and demonstrated that bacterial killing was due to the activity of the antibiotics (data not shown). *P. aeruginosa* colony counts in rat lung dropped at least 3 log10 with treatment and the organisms were eradicated with higher doses of FTI. While the *in vivo* activity of FTI is slightly less than that of tobramycin on a weight basis, tobramycin accounts for only 20% of FTI. The tobramycin MIC for C177 (0.5 mg/L) is 8-fold less than the FTI MIC (4 mg/L) and may explain the slight difference in activity. Fosfomycin alone has very little activity against *P. aeruginosa* in vivo and confirms the *in vitro* data presented in this study.

Development of antibiotic resistance is of particular concern in bronchiectasis patients. Antibiotic options are limited and bacterial isolates, particularly those from CF individuals, are resistant to many of the currently approved antibiotics. The spontaneous mutation frequency resulting in development of antibiotic resistance is of particular concern in bronchiectasis patients. Antibiotic options are limited and bacterial isolates, particularly those from CF individuals, are resistant to many of the currently approved antibiotics. The spontaneous mutation frequency resulting in resistance after a single exposure was dramatically less than the frequencies of fosfomycin or tobramycin for *S. aureus* and *P. aeruginosa*.

| Organism (strain) | FTI | Fosfomycin | Tobramycin |
|------------------|-----|------------|------------|
| *S. aureus*      |     |            |            |
| C051             | <1.8×10^{-10} | 3.0×10^{-5} | 3.5×10^{-6} |
| C053             | <1.8×10^{-10} | 7.7×10^{-3} | 2.0×10^{-7} |
| C055             | <4.3×10^{-9}  | 2.5×10^{-6} | 3.8×10^{-7} |
| C057             | 1.0×10^{-9}   | 2.1×10^{-5} | 1.1×10^{-6} |
| ATCC 29213       | <3.1×10^{-10} | 2.6×10^{-8} | 1.6×10^{-7} |
| *P. aeruginosa*  |     |            |            |
| C002             | 5.0×10^{-6}   | 6.5×10^{-3} | 1.1×10^{-5} |
| C003             | 1.1×10^{-6}   | 1.1×10^{-6} | 4.2×10^{-5} |
| C013             | 1.2×10^{-7}   | 9.2×10^{-3} | 1.4×10^{-6} |
| C014             | 3.4×10^{-6}   | 1.4×10^{-4} | 1.3×10^{-5} |
| ATCC 27853       | 4.6×10^{-7}   | 7.2×10^{-4} | 3.0×10^{-5} |

Figure 2. Reduction of *P. aeruginosa* (strain C177) cfu in the rat lung after intratracheal administration of antibiotic twice daily for 3 days. (a) FTI. (b) Tobramycin. (c) Fosfomycin. Data are expressed as means±SD. P<0.05; **P<0.01. PreTx, pre-treatment.
Fosfomycin/tobramycin combination for bronchiectasis

Fosfomycin resistance occurred very rapidly after a single in vitro exposure, in our studies. This finding is consistent with previous reports. However, evidence for the in vivo development of fosfomycin resistance is lacking. Fosfomycin has been extensively used for >20 years in Japan and Europe for the treatment of urinary tract infections. Despite this, the reported fosfomycin resistance in urinary E. coli isolates remains <2%. Antibiotic options for CF or non-CF bronchiectasis patients are limited. FTI, a novel antibiotic combination, has many desirable properties. Pre-clinical research demonstrates that FTI is active against important CF and non-CF respiratory pathogens including S. aureus, H. influenzae, M. catarrhalis, coliforms and multidrug-resistant P. aeruginosa. FTI was rapidly bactericidal and had activity comparable to that of tobramycin. Moreover, FTI reduced the development of antibiotic resistance. Fosfomycin, the major component of FTI, has a very favourable safety profile when administered parenterally. Additionally, several studies have shown that fosfomycin reduces aminoglycoside-induced nephrotoxicity. Since tobramycin constitutes 20% of FTI on a weight basis, the cumulative toxic effects due to tobramycin could also be reduced. The comparative safety of FTI should ultimately be evaluated in future studies in the affected populations. These data suggest that FTI should be investigated further for the treatment of CF and non-CF bronchiectasis infections.

Acknowledgements

We thank Chad Nicely and Chris Hardwick for developing the microbiology database as well as Lisa Moorehead and Benjamin Duncan for their assistance with statistical analysis of the animal efficacy data. We also thank Geri Orta, Jolene Kidney and Lisa Corey for assisting with the animal efficacy work. Subsets of the MIC, resistance and animal efficacy data were presented at the Twenty-first Annual North American Cystic Fibrosis Conference, Anaheim, CA, USA, 2007 (Abstract 328).

Funding

This study was supported by Gilead Sciences, Inc.

Transparency declarations

D. L. M., T. F. K and W. R. B. are currently employed by Gilead Sciences, Inc. D. L. M., W. R. B. and T. F. K. own stock and options in Gilead Sciences, Inc. J. L. B. serves as a consultant for Gilead Sciences, Inc.

References

1. Anonymous. Cystic Fibrosis Foundation Patient Registry Annual Report. Bethesda, MD, USA: Cystic Fibrosis Foundation, 2003.
2. Conway SP, Brownlee KG, Denton M et al. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841–9.
3. Sykes A, Mailia P, Johnston SL. Diagnosis of pathogens in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 642–6.
4. Gibson RL, Emerson J, McNamara S et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841–9.
5. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23–30.
6. Mirakhur A, Gallagher MJ, Ledson MJ et al. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003; 2: 19–24.
7. Saiman L, Chen Y, Gabriel PS et al. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002; 46: 1105–7.
8. Kahan FM, Kahan JS, Cassidy PJ et al. The mechanism of action of fosfomycin (phosphonomycin). Ann NY Acad Sci 1974; 235: 364–86.
9. Woodruff HB, Mata JM, Hernandez S et al. Fosfomycin: laboratory studies. Chemotherapy 1977; 23 Suppl 1: 1–22.
10. Grif K, Dierich MP, Pfaller K et al. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001; 48: 209–17.
11. Menendez A, Tutor A, Sousa AS. Treatment of respiratory infections with fosfomycin. Chemotherapy 1977; 23 Suppl 1: 348–57.
12. Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49: 403–6.
13. Shimizu M, Shigoebu F, Miyakozawa I et al. Novel fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996. Antimicrob Agents Chemother 2000; 44: 2007–8.
14. Katznelson D, Yahav Y, Rubinstein E. Fosfomycin in the treatment of cystic fibrosis. Eur J Clin Microbiol 1984; 3: 213.
15. Shawar RM, MacLeod DL, Garber RL et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 2877–80.
16. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003; 16: 430–50.
17. Hammelt-Stubler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. Clin Chem 1998; 44: 1129–40.
18. Al-Aloul M, Miller H, Alapati S et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39: 15–20.
19. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically—Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
20. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing—Fourteenth Edition: Approved Standard M100-S13. NCCLS, Wayne, PA, USA, 2003.
21. National Committee for Clinical Laboratory Standards. Methods for Determining Bacterial Activity of Antimicrobial Agents—Approved Standard M26-A. NCCLS, Wayne, PA, USA, 1999.
22. Eliopoulos GM, Moellingcr RC Jr. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Baltimore: Williams & Wilkins Co., 1996; 330–96.
23. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Baltimore: Williams & Wilkins Co., 1996; 326–329.
24. NRC (National Research Council). Guide for the Care and Use of Laboratory Animals. Washington, DC, USA: National Academy Press, 1996.
25. Cash HA, Woods DE, McCullough B et al. A rat model of chronic respiratory infection with *Pseudomonas aeruginosa*. *Am Rev Respir Dis* 1979; 119: 453–9.

26. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. *Antimicrob Agent Chemother* 2000; 44: 1771–7.

27. Nilsson AI, Berg OG, Aspevall O et al. Biological costs and mechanisms of fosfomycin resistance in *Escherichia coli*. *Antimicrob Agents Chemother* 2003; 47: 2850–8.

28. Hunt BE, Weber A, Berger A et al. Macromolecular mechanisms of sputum inhibition of tobramycin activity. *Antimicrob Agents Chemother* 1995; 39: 34–9.

29. Mendelman PM, Smith AL, Levy J et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. *Am Rev Respir Dis* 1985; 132: 761–5.

30. Hayami H, Goto T, Kawahara M et al. Activities of β-lactams, fluoroquinolones, amikacin, and fosfomycin alone and in combination against *Pseudomonas aeruginosa* isolated from complicated urinary tract infections. *J Infect Chemother* 1999; 5: 130–8.

31. Tessier F, Quentin C. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis* 1997; 16: 159–62.

32. Smith AL, Doershuk C, Goldmann D et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. *J Pediatr* 1999; 134: 413–21.

33. Inouye S, Niizato T, Takeda U et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. *J Pharmacobiodyn* 1982; 5: 659–69.

34. Inouye S, Niizato T, Komiya I et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. *J Pharmacobiodyn* 1982; 5: 941–50.

35. Yanagida C, Ito K, Komiya I et al. Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. *Chem Biol Interact* 2004; 148: 139–47.